Drug Search Results
More Filters [+]

EDP-239

Alternative Names: edp-239, edp239, edp 239
Latest Update: 2016-01-29
Latest Update Note: Clinical Trial Update

Product Description

EDP-239 is Enantas lead NS5A inhibitor for HCV infection

Mechanisms of Action: HCV-NS5A Inhibitor

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Enanta
Company Location: WATERTOWN MA 02472
Company CEO: Jay R. Luly
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EDP-239

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Hepatitis C|Hepatitis A

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CDEB025A2119

P1

Completed

Hepatitis C

2014-11-01

CEDP239X2201

P1

Completed

Hepatitis A|Hepatitis C

2014-11-01

Recent News Events

Date

Type

Title